Chacko, George; Tufano, Peter; Verter, Geoffrey - In: Journal of Applied Corporate Finance 15 (2002) 1, pp. 57-70
In early 1997, Cephalon, Inc., a biotechnology firm, purchased 2.5 million capped call options on its own stock, with a potential value of as much as $45 million, in exchange for $9.8 million worth of its common shares. Cephalon's first major drug, Myotrophin, was under review by the U.S. Food...